샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513906

세계의 과민성 대장 증후군(IBS) 치료제 시장

Irritable Bowel Syndrome (IBS) Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 269 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

과민성 대장 증후군(IBS) 치료제 세계 시장은 2030년까지 34억 달러에 달할 전망

2023년에 21억 달러로 추정되는 과민성 대장 증후군(IBS) 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 7.2%로 성장하고, 2030년에는 34억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 IBS-D 치료제는 CAGR 6.9%로 성장을 지속하고, 분석 기간 종료까지 19억 달러에 달할 것으로 예측됩니다. IBS-C 치료제 부문의 성장률은 분석 기간 동안 CAGR 7.5%로 추정됩니다.

미국 시장은 5억 6,590만 달러로 추정, 중국은 CAGR 11.5%로 성장 예측

미국의 과민성 대장 증후군(IBS) 치료제 시장은 2023년 5억 6,590만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 7억9,180만 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 11.5%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.7%와 7.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계의 과민성 대장 증후군(IBS) 치료제 시장 - 주요 동향 및 촉진요인 요약

과민성 대장 증후군(IBS)은 대장을 침범하고 복통, 복부 팽만감, 변비, 설사 등의 증상을 나타내는 일반적인 위장 질환입니다. 생명을 위협하지는 않지만 IBS는 삶의 질을 크게 저하시키고 건강 관리 시스템에 큰 경제적 부담을 가하고 있습니다. 역사적으로 IBS는 제외 검사에 의해 진단되어 왔지만, 현재는 상세한 병력 청취와 신체 진찰 이외에, Rome III와 같은 기준을 이용함으로써 보다 신속한 동정이 가능해지고 있습니다. 이 질환은 장의 습관 변화와 관련된 만성 복부 불쾌감과 복통을 특징으로하며, 증상은 진단 최소 6 개월 전부터 시작하여 지난 3 개월 동안 한 달에 3 일 이상 발생해야합니다. 이러한 현대적인 이해는 진단 과정을 간소화하는 데 도움이되며, 특히 의도하지 않은 체중 감소 및 빈혈과 같은 심각한 지표가없는 전형적인 IBS 증상을 나타내는 젊은 환자에서 불필요하고 비용이 많이 듭니다. 검사를 피할 수 있습니다.

IBS의 치료법은 해마다 다양해지고, 식이섬유 보조식품이나 근이완제 등의 종래의 선택에 머무르지 않고, 식생활의 개선이나 프로바이오틱스, 항생물질, 삼환계 항우울제(TCA)나 선택적 세로토닌 재 흡수 억제제(SSRI)와 같은 약물 조합과 같은 주요 증상에 따라 맞춤형 치료가 수행됩니다. 진경제는 효과가 한정적이고 부작용이 크기 때문에 TCA나 SSRI와 같은 중추와 말초 모두에서 통증의 지각을 조절하는 약에 중점이 옮겨가고 있습니다. 또한, 식사 관리, 특히 높은 FODMAP 음식의 감소와 프로바이오틱스의 사용은 복부 팽만감과 기타 소화기계 불편 증상의 관리에 필수적입니다. 변비나 설사를 주증상으로 하는 IBS에 대해서는 변비에는 루비프로스톤이나 리나클로티드, 설사에는 아로세트론이나 리팍시민 등의 새로운 약제가 장애의 특정 기능적 증상을 표적으로 함으로써 치료 효과를 높여 합니다.

IBS 치료제 시장의 성장을 가속하는 요인은 여러 가지가 있습니다. 로마 IV 가이드라인의 시행 등 진단 기술의 진보로 IBS 진단의 정확도가 향상되고, 보다 적당한 치료 접근이 촉진되고 있습니다. 또한 미디어와 환자 지원 단체, 헬스케어 이니셔티브에 뒷받침되는 형태로 소비자의 의식과 관여가 높아져 효과적인 치료법에 대한 수요가 높아지고 있습니다. 원격 의료 서비스 및 증상 추적 및 관리를 위한 모바일 헬스 용도을 포함한 디지털 헬스 솔루션의 통합은 지속적인 환자 모니터링과 맞춤 치료 튜닝을 지원합니다. 또한, 장내 세균총의 수정을 목적으로 하는 표적 약리학적 약제의 개발이나 보험 적용 범위의 확대, 고액이지만 보다 새로운 치료를 지지하는 헬스케어 정책에 의해 이러한 치료에의 액세스가 향상 하고 있습니다. 이러한 진보는 적극적인 환자 지원 프로그램과 규제 상황의 진화와 함께 IBS 환자 증가하는 요구에 부응하고 그 관리 전반과 생활의 질을 향상시키기 위해 필수적입니다.

조사 대상 기업 예(총 12건)

  • Allergan PLC
  • Astellas Pharma, Inc.
  • IM HealthScience
  • Mallinckrodt Pharmaceuticals
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach US$3.4 Billion by 2030

The global market for Irritable Bowel Syndrome (IBS) Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the IBS-C Therapeutics segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$565.9 Million While China is Forecast to Grow at 11.5% CAGR

The Irritable Bowel Syndrome (IBS) Therapeutics market in the U.S. is estimated at US$565.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$791.8 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Irritable Bowel Syndrome (IBS) Therapeutics Market - Key Trends and Drivers Summarized

Irritable Bowel Syndrome (IBS) is a prevalent gastrointestinal disorder that affects the large intestine, manifesting symptoms such as abdominal pain, bloating, constipation, and diarrhea. Although not life-threatening, IBS substantially reduces quality of life and imposes a significant economic burden on healthcare systems. Historically, IBS was diagnosed by exclusion, but advancements now allow for quicker identification using criteria such as the Rome III, alongside a detailed medical history and physical examination. This disorder is characterized by chronic abdominal discomfort or pain associated with altered bowel habits, with symptoms needing to have started at least six months before diagnosis and occurring at least three days per month in the last three months. This contemporary understanding helps streamline the diagnostic process, avoiding unnecessary and costly tests, especially in younger patients presenting typical IBS symptoms without severe indicators such as unintentional weight loss or anemia.

The treatment landscape for IBS has diversified over the years, moving beyond conventional options like fiber supplements and muscle relaxants to include tailored treatments based on predominant symptoms—ranging from dietary changes and probiotics to antibiotics and combinations of medications such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). There's a shifting emphasis from antispasmodics, due to their limited efficacy and significant side effects, towards TCAs and SSRIs that modulate pain perception both centrally and peripherally. Additionally, dietary management, particularly the reduction of high-FODMAP foods, and the use of probiotics have become integral in managing bloating and other digestive discomforts. For constipation and diarrhea predominant IBS, newer medications like lubiprostone and linaclotide for constipation, and alosetron and rifaximin for diarrhea, are enhancing therapeutic outcomes by targeting specific functional symptoms of the disorder.

Several factors are driving growth in the IBS therapeutics market. Advances in diagnostic technologies, such as the implementation of the Rome IV guidelines, have refined the accuracy of IBS diagnosis, fostering a more targeted therapeutic approach. There is also an increased consumer awareness and engagement, partly fueled by media, patient advocacy groups, and healthcare initiatives, which heighten demand for effective treatments. The integration of digital health solutions, including telehealth services and mobile health applications for symptom tracking and management, supports continuous patient monitoring and personalized treatment adjustments. Furthermore, the development of targeted pharmacological agents aimed at modifying gut flora, and expanding insurance coverage and healthcare policies that favor newer, albeit more costly, treatments are enhancing access to these therapies. These advancements, alongside active patient support programs and evolving regulatory landscapes, are essential for meeting the growing needs of IBS patients and improving their overall management and quality of life.

Select Competitors (Total 12 Featured) -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • IM HealthScience
  • Mallinckrodt Pharmaceuticals
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Irritable Bowel Syndrome (IBS) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of IBS Propels Demand for Effective Therapeutics
    • Advances in Gut Microbiome Research Strengthen Business Case for Novel IBS Treatments
    • Increasing Awareness and Diagnosis of IBS Expands Addressable Market Opportunity
    • Focus on Personalized Medicine Drives Adoption of Tailored IBS Therapeutics
    • Growing Geriatric Population and Associated Digestive Disorders Spur Growth in IBS Therapeutics Market
    • Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
    • Advances in Probiotics and Prebiotics Propel Development of Innovative IBS Treatments
    • Increasing Focus on Non-Pharmacological Therapies: Here's the Story of Complementary Treatment Approaches
    • Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Novel Therapies
    • Growing Adoption of Digital Health Solutions Expands Access to IBS Treatment and Management
    • Advances in Molecular Diagnostics Propel Growth in Precision Medicine for IBS
    • Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
    • Advances in Drug Delivery Systems Propel Development of Novel IBS Therapeutics
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
    • Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
    • Increasing Focus on Integrative and Complementary Therapies Drives Demand for Comprehensive IBS Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for IBS-D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for IBS-D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for IBS-D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for IBS-C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for IBS-C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for IBS-C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Linzess / Constella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Linzess / Constella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Linzess / Constella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Xifaxan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Xifaxan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Xifaxan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Viberzi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Viberzi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Viberzi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Amitiza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Amitiza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Amitiza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • JAPAN
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • CHINA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • EUROPE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • GERMANY
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • INDIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • AFRICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제